Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 Million

Wall Street brokerages expect United Therapeutics Co. (NASDAQ:UTHR) to post sales of $415.79 million for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for United Therapeutics’ earnings, with estimates ranging from $391.85 million to $477.41 million. United Therapeutics reported sales of $409.00 million in the same quarter last year, which indicates a positive year over year growth rate of 1.7%. The company is expected to issue its next earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that United Therapeutics will report full year sales of $415.79 million for the current year, with estimates ranging from $1.65 billion to $1.74 billion. For the next fiscal year, analysts forecast that the firm will report sales of $1.38 billion per share, with estimates ranging from $1.29 billion to $1.47 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. During the same period in the prior year, the business posted $4.23 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis.

Several equities research analysts have recently weighed in on UTHR shares. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. ValuEngine upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. Zacks Investment Research upgraded United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Wedbush reiterated an “outperform” rating and issued a $232.00 price target (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Finally, Cowen reiterated a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $140.45.

Shares of United Therapeutics (UTHR) traded down $6.15 during midday trading on Tuesday, hitting $135.12. The stock had a trading volume of 627,905 shares, compared to its average volume of 399,880. United Therapeutics has a 12-month low of $112.01 and a 12-month high of $169.89. The stock has a market capitalization of $5,890.00, a P/E ratio of 11.92 and a beta of 1.41.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,269 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $118.04, for a total transaction of $149,792.76. Following the transaction, the chief executive officer now directly owns 1,409 shares in the company, valued at approximately $166,318.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. Following the transaction, the director now owns 2,135 shares in the company, valued at $260,470. The disclosure for this sale can be found here. Insiders have sold a total of 15,773 shares of company stock worth $1,925,637 over the last 90 days. 7.80% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. First Allied Advisory Services Inc. boosted its position in United Therapeutics by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after acquiring an additional 19 shares in the last quarter. Fort L.P. boosted its position in United Therapeutics by 5.2% during the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares in the last quarter. Guardian Capital LP boosted its position in United Therapeutics by 5.9% during the 2nd quarter. Guardian Capital LP now owns 2,623 shares of the biotechnology company’s stock valued at $340,000 after acquiring an additional 145 shares in the last quarter. M&T Bank Corp boosted its position in United Therapeutics by 8.8% during the 2nd quarter. M&T Bank Corp now owns 2,217 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 179 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in United Therapeutics by 8.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,272 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 180 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 Million” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/01/16/analysts-expect-united-therapeutics-co-uthr-will-post-quarterly-sales-of-415-79-million.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply